Houston-based gene therapy outfit files for $70M IPO

At the end of last year, the small, Houston-based gene therapy company MultiVir had about a half-million dollars in the bank, working on two cancer drugs. Now the low-profile biotech--which operated on a $4 million budget for the last two years--has filed for a $70 million IPO with plans to advance its lead program for Ad-p53, "a genetically modified adenovirus designed to deliver the normal p53 tumor suppressor gene." A large part of its technology was originally developed at Introgen, a controversial Texas biotech that filed for bankruptcy back in 2008 and liquidated in 2010 after raising more than $700 million. CEO Robert Sobol, who counts himself as one of the original co-founders of Idec in 1985, well ahead of its merger with Biogen, was the SVP at Introgen from 2003 to 2008. S-1

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.